Showing posts with label Hayfever. Show all posts
Showing posts with label Hayfever. Show all posts
Friday, 4 March 2011
'Tree pollen season' is upon us
The tree pollen season is already upon us with many patients experiencing early symptoms. You may wish to keep an 'eye' on local pollen reports, most of which only start reporting from later on in March. Anticipate more severe symptoms when levels are higher and ensure medications such as non-sedating antihistamines are taken in advance. Immunotherapy is available as a curative approach for those with moderate to severe grass and/or tree pollen allergies.
Labels:
Allergic Rhintis,
conjunctivitis,
Hayfever,
Immunotherapy,
Pollen
Tuesday, 11 January 2011
December 13, 2010 — Sublingual immunotherapy may be safe and effective for allergic rhinitis, according to an updated review reported online December
Allergic rhinitis has been reported in up to 40% of people worldwide. According to the 2008 guidelines on Allergic Rhinitis and its Impact on Asthma (ARIA), published in the April 2008 supplemental issue of Allergy, specific immunotherapy is recommended for patients with severe allergic rhinitis who do not respond to allergen avoidance and pharmacotherapy.
The 2003 Cochrane Review of sublingual immunotherapy for allergic rhinitis by Wilson and colleagues, published in the 2003 issue of the Cochrane Database of Systematic Reviews, included 22 randomized, placebo-controlled trials. Sublingual immunotherapy was noted to be effective and was not associated with systemic reactions.
This update of the 2003 Cochrane Review evaluates the efficacy and safety of sublingual immunotherapy for allergic rhinitis in adults and children.
Study Highlights
•A search of the literature included the Cochrane ENT Disorders Group Trials Register, the Cochrane Central Register of Controlled Trials, PubMed, EMBASE, CINAHL, LILACS, KoreaMed, IndMed, PakMediNet, CAB Abstracts, Web of Science, BIOSIS Previews, China National Knowledge Infrastructure, Current Controlled Trials, International Clinical Trials Registry Platform, Google, reference lists, and other sources for published and unpublished data through August 14, 2009.
•Inclusion criteria were randomized, double-blind, placebo-controlled clinical trials that assessed the efficacy and safety of sublingual immunotherapy in adults and children with allergic rhinitis and a Jadad score greater than 3 of 5.
•60 studies were identified.
•49 studies were included in the efficacy meta-analysis.
•11 studies lacked efficacy data but had adverse event data.
•Subjects had allergic rhinitis with or without allergic conjunctivitis or allergic asthma.
•Allergens were identified by skin prick tests or high specific immunoglobulin E results.
•34 studies had adult participants, and 15 studies had children as participants.
•The primary outcome measures were symptom scores and medication scores.
•Symptom scores were assessed by diaries, visual analog scales, number of well days, or overall assessment.
•Medication scores assessed the use of antihistamine tablets, nasal sprays, and eye drops.
•Secondary outcome measures were serum immunoglobulin E and immunoglobulin G levels; allergen sensitivity of the eye, nose, or skin; and reports of adverse events.
•Subgroup analysis was conducted for seasonal vs perennial allergens, children vs adults, major allergen dose (< 5 μg vs 5 to 20 μg vs > 20 μg), duration of immunotherapy (< 6 months vs 6 - 12 months vs 12 months), individual allergens (house dust mite, grass pollen, Parietaria, ragweed, tree), sublingual spit vs swallow, and sublingual drops vs tablets.
•Symptom scores improved more in 2333 patients receiving sublingual immunotherapy vs 2256 patients receiving placebo. The SMD was −0.49 (P < .00001), based on 49 studies.
•Medication scores improved more in 1737 patients receiving sublingual immunotherapy vs 1642 patients receiving placebo (SMD, −0.32; P < .00001), based on 38 studies.
•Serum-specific immunoglobulin E levels increased in 675 patients receiving sublingual immunotherapy vs 659 patients receiving placebo (SMD, 0.27; P = .05), based on 14 studies.
•Total serum-specific immunoglobulin G levels increased in 286 patients receiving sublingual immunotherapy vs 304 patients receiving placebo (SMD, 0.95; P < .00001), based on 3 studies.
•Serum-specific immunoglobulin G4 levels increased in 588 patients receiving sublingual immunotherapy vs 599 patients receiving placebo (SMD, 0.46; P < .00001).
•Allergen sensitivity, measured by skin prick test results and nasal reactivity, did not significantly differ between the sublingual immunotherapy group and the placebo group.
•25 studies could not be included in adverse event analysis.
•Local adverse events, including labial edema, buccal pruritus, buccal or lingual edema, and throat irritation, were more common in the sublingual immunotherapy group vs the placebo group.
•Adverse events leading to treatment discontinuation occurred in 41 of 824 patients in the sublingual immunotherapy group and 12 of 861 patients in the placebo group, with local reactions occurring more than systemic reactions.
•No adverse events required adrenaline use.
•No fatalities occurred.
•Systemic adverse events were mild or moderate.
•No severe systemic adverse events or anaphylaxis events occurred.
•Subgroup analysis of symptom scores showed more improvement in the sublingual immunotherapy group vs the placebo group for all subgroups except for a major allergen content of less than 5 μg.
•Subgroup analysis of medication scores showed more improvement in the sublingual immunotherapy group vs the placebo group for all subgroups except for perennial allergens, children, house dust mite allergen, and sublingual drops.
Clinical Implications
•In adults and children with allergic rhinitis, sublingual immunotherapy is effective in reducing symptoms and the need for medication.
•In adults and children who receive sublingual immunotherapy for allergic rhinitis, reported adverse events include local and systemic mild and moderate events, but no severe systemic reactions, anaphylaxis, or the need for adrenaline.
The 2003 Cochrane Review of sublingual immunotherapy for allergic rhinitis by Wilson and colleagues, published in the 2003 issue of the Cochrane Database of Systematic Reviews, included 22 randomized, placebo-controlled trials. Sublingual immunotherapy was noted to be effective and was not associated with systemic reactions.
This update of the 2003 Cochrane Review evaluates the efficacy and safety of sublingual immunotherapy for allergic rhinitis in adults and children.
Study Highlights
•A search of the literature included the Cochrane ENT Disorders Group Trials Register, the Cochrane Central Register of Controlled Trials, PubMed, EMBASE, CINAHL, LILACS, KoreaMed, IndMed, PakMediNet, CAB Abstracts, Web of Science, BIOSIS Previews, China National Knowledge Infrastructure, Current Controlled Trials, International Clinical Trials Registry Platform, Google, reference lists, and other sources for published and unpublished data through August 14, 2009.
•Inclusion criteria were randomized, double-blind, placebo-controlled clinical trials that assessed the efficacy and safety of sublingual immunotherapy in adults and children with allergic rhinitis and a Jadad score greater than 3 of 5.
•60 studies were identified.
•49 studies were included in the efficacy meta-analysis.
•11 studies lacked efficacy data but had adverse event data.
•Subjects had allergic rhinitis with or without allergic conjunctivitis or allergic asthma.
•Allergens were identified by skin prick tests or high specific immunoglobulin E results.
•34 studies had adult participants, and 15 studies had children as participants.
•The primary outcome measures were symptom scores and medication scores.
•Symptom scores were assessed by diaries, visual analog scales, number of well days, or overall assessment.
•Medication scores assessed the use of antihistamine tablets, nasal sprays, and eye drops.
•Secondary outcome measures were serum immunoglobulin E and immunoglobulin G levels; allergen sensitivity of the eye, nose, or skin; and reports of adverse events.
•Subgroup analysis was conducted for seasonal vs perennial allergens, children vs adults, major allergen dose (< 5 μg vs 5 to 20 μg vs > 20 μg), duration of immunotherapy (< 6 months vs 6 - 12 months vs 12 months), individual allergens (house dust mite, grass pollen, Parietaria, ragweed, tree), sublingual spit vs swallow, and sublingual drops vs tablets.
•Symptom scores improved more in 2333 patients receiving sublingual immunotherapy vs 2256 patients receiving placebo. The SMD was −0.49 (P < .00001), based on 49 studies.
•Medication scores improved more in 1737 patients receiving sublingual immunotherapy vs 1642 patients receiving placebo (SMD, −0.32; P < .00001), based on 38 studies.
•Serum-specific immunoglobulin E levels increased in 675 patients receiving sublingual immunotherapy vs 659 patients receiving placebo (SMD, 0.27; P = .05), based on 14 studies.
•Total serum-specific immunoglobulin G levels increased in 286 patients receiving sublingual immunotherapy vs 304 patients receiving placebo (SMD, 0.95; P < .00001), based on 3 studies.
•Serum-specific immunoglobulin G4 levels increased in 588 patients receiving sublingual immunotherapy vs 599 patients receiving placebo (SMD, 0.46; P < .00001).
•Allergen sensitivity, measured by skin prick test results and nasal reactivity, did not significantly differ between the sublingual immunotherapy group and the placebo group.
•25 studies could not be included in adverse event analysis.
•Local adverse events, including labial edema, buccal pruritus, buccal or lingual edema, and throat irritation, were more common in the sublingual immunotherapy group vs the placebo group.
•Adverse events leading to treatment discontinuation occurred in 41 of 824 patients in the sublingual immunotherapy group and 12 of 861 patients in the placebo group, with local reactions occurring more than systemic reactions.
•No adverse events required adrenaline use.
•No fatalities occurred.
•Systemic adverse events were mild or moderate.
•No severe systemic adverse events or anaphylaxis events occurred.
•Subgroup analysis of symptom scores showed more improvement in the sublingual immunotherapy group vs the placebo group for all subgroups except for a major allergen content of less than 5 μg.
•Subgroup analysis of medication scores showed more improvement in the sublingual immunotherapy group vs the placebo group for all subgroups except for perennial allergens, children, house dust mite allergen, and sublingual drops.
Clinical Implications
•In adults and children with allergic rhinitis, sublingual immunotherapy is effective in reducing symptoms and the need for medication.
•In adults and children who receive sublingual immunotherapy for allergic rhinitis, reported adverse events include local and systemic mild and moderate events, but no severe systemic reactions, anaphylaxis, or the need for adrenaline.
Labels:
Allergic Rhintis,
Hayfever,
Immunotherapy,
Rhinitis
Wednesday, 29 December 2010
Optimum duration of dust mite sublingual immunotherapy (SLIT).
There is an increasing body of evidence to support the use of Sub Lingual Immunotherapy for the treatment of House Dust Mite Allergy, it may however be that a 4an style="font-weight:bold;">-year course of sublingual immunotherapy (SLIT) would be the optimum duration for allergic rhinitis patients sensitised to dust mite allergens.
Recently, Marogna M, Spadolini I, Massolo A et al. Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year prospective study. Journal of Allergy and Clinical Immunology investigate the long-term effects of SLIT, and the optimal duration of treatment, by studying 78 patients aged 18-65 years, with allergic rhinitis (with or without asthma), who were monosensitized to dust mites.
The participants were divided into four groups to receive mite-specific SLIT plus drug therapy for 3 (n=19), 4 (n=21), or 5 years (n=17), or drug therapy alone (controls; n=21). Clinical benefit, based on the frequency and severity of symptoms, were assessed every year during the winter months over a follow-up period of 15 years. During this time, 10 patients receiving SLIT and nine controls dropped out of the study. There was no significant change in clinical scores among the 12 controls. In patients receiving SLIT, a significant clinical benefit was observed after just 1 year, which persisted for 7 years among patients who received SLIT for 3 years, and 8 years among those who received SLIT for 4 or 5 years. After loss of clinical benefit, patients in the SLIT groups received a second course of treatment, and this induced a benefit more rapidly than the first course. All patients in the control group developed a new skin sensitization during the follow-up period compared with just 21%, 12%, and 11% of patients who received SLIT for 3, 4, and 5 years, respectively.
They concluded that under the present conditions, it can be suggested that a 4-year duration of SLIT is the optimal choice because it induces a long-lasting clinical improvement similar to that seen with a 5-year course and greater than that of a 3-year vaccination.
Recently, Marogna M, Spadolini I, Massolo A et al. Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year prospective study. Journal of Allergy and Clinical Immunology investigate the long-term effects of SLIT, and the optimal duration of treatment, by studying 78 patients aged 18-65 years, with allergic rhinitis (with or without asthma), who were monosensitized to dust mites.
The participants were divided into four groups to receive mite-specific SLIT plus drug therapy for 3 (n=19), 4 (n=21), or 5 years (n=17), or drug therapy alone (controls; n=21). Clinical benefit, based on the frequency and severity of symptoms, were assessed every year during the winter months over a follow-up period of 15 years. During this time, 10 patients receiving SLIT and nine controls dropped out of the study. There was no significant change in clinical scores among the 12 controls. In patients receiving SLIT, a significant clinical benefit was observed after just 1 year, which persisted for 7 years among patients who received SLIT for 3 years, and 8 years among those who received SLIT for 4 or 5 years. After loss of clinical benefit, patients in the SLIT groups received a second course of treatment, and this induced a benefit more rapidly than the first course. All patients in the control group developed a new skin sensitization during the follow-up period compared with just 21%, 12%, and 11% of patients who received SLIT for 3, 4, and 5 years, respectively.
They concluded that under the present conditions, it can be suggested that a 4-year duration of SLIT is the optimal choice because it induces a long-lasting clinical improvement similar to that seen with a 5-year course and greater than that of a 3-year vaccination.
Labels:
Asthma,
Duration,
Hayfever,
House Dust Mite Allergy,
Immunotherapy,
Rhinitis
Subscribe to:
Posts (Atom)